11. Development of a Multiplexed SRM Assay for Osteoarthritis Biomarkers
Tue 12:00 PM - PosterSplash Track 2
Bryan Krastins
Thermo Fisher Scientific
Bryan Krastins, Thermo Fisher Scientific
David Lee, Brigham and Women's Hospital
Reuben Gobezie, Case Western University David Sarracino, Thermo Fisher Scientific
Amol Prakash, Thermo Fisher Scientific
Taha Rezai, Thermo Fisher Scientific
Richard Jones, NextGen Sciences
Michael Pisano, NextGen Sciences
Mary F Lopez, Thermo Fisher Scientific
Michael Ford, NextGen Sciences
Osteoarthritis (OA) is a prevalent, poorly understood disease whose management would be significantly advanced by the development of assays for early diagnosis and/or disease prognosis. Previous discovery work has identified candidate protein biomarkers for OA (1) including afamin and proteoglycan 4. Recently, emphasis has been placed on advancing proteomics studies from discovery and/or relative quantitation to validated quantitative methods in an effort to establish clinical assays. Targeted selective ion monitoring (SRM) assays provide a vehicle for cost effective, high-throughput quantification and monitoring of specific disease biomarkers. In this study, we applied novel software to integrate information from MS/MS discovery spectra generated on an LTQOrbitrap™ platform to facilitate the development of osteoarthritis specific SRM assays on a TSQVantage™ triple quadrupole mass spectrometer. The SRM assays were used to interrogate over 200 clinical patient samples and demonstrate the applicability of this approach for potential OA screening. The results of this preliminary study demonstrate high inter-laboratory reproducibility of the assay as well the classification power of the surrogate peptide SRM assays.

1.Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007;9(2):R36.